XML 56 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Supplemental Income Statement Information (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenues
Revenues by type are as follows:
(In millions)202420232022
Revenues
Consumables
$17,587 $17,597 $20,624 
Instruments
7,446 7,646 7,924 
Services
17,845 17,614 16,367 
Consolidated revenues
$42,879 $42,857 $44,915 
Revenues by geographic region based on customer location are as follows:
(In millions)202420232022
Revenues
North America
$22,504 $22,764 $24,594 
Europe
10,857 10,741 10,762 
Asia-Pacific
7,956 7,873 8,115 
Other regions
1,561 1,479 1,444 
Consolidated revenues
$42,879 $42,857 $44,915 
Schedule of Restructuring and Other Costs by Segment
Restructuring and other costs by segment are as follows:
(In millions)202420232022
Life Sciences Solutions
$69 $105 $30 
Analytical Instruments
4 33 1 
Specialty Diagnostics
17 11 68 
Laboratory Products and Biopharma Services
280 295 12 
Corporate
9 15 3 
$379 $459 $114 
Schedule of Changes in the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2021$17 
Net restructuring charges incurred in 2022 (b)
68 
Payments
(44)
Balance at December 31, 202241 
Net restructuring charges incurred in 2023 (c) (d)
194 
Payments
(175)
Balance at December 31, 202360 
Net restructuring charges incurred in 2024 (e) (f)
97 
Payments
(105)
Currency translation
(2)
Balance at December 31, 2024$50 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $46 million of charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
(c)Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.
(d)Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.
(e)Excludes $282 million of net charges, principally $211 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments.
(f)Excludes $41 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $19 million attributable to a noncontrolling interest.
Schedule of Earnings Per Share
The company’s earnings per share are as follows:
(In millions except per share amounts)202420232022
Net income attributable to Thermo Fisher Scientific Inc.
$6,335 $5,995 $6,950 
Basic weighted average shares
382 386 392 
Plus effect of: stock options and restricted stock units
1 2 2 
Diluted weighted average shares
383 388 394 
Basic earnings per share
$16.58 $15.52 $17.75 
Diluted earnings per share
$16.53 $15.45 $17.63 
Antidilutive stock options excluded from diluted weighted average shares
2 2 2